Immunome Issues Private Equity Shares to Ayala
Company Announcements

Immunome Issues Private Equity Shares to Ayala

Immunome (IMNM) has released an update to notify the public and investors about the unregistered sales of equity securities.

Shares will be issued to Ayala at the Closing, utilizing an exemption from registration requirements under Section 4(a)(2) of the Securities Act, which applies to private transactions by an issuer. As a result, these shares won’t be publicly registered and can’t be sold in the U.S. without proper registration or a relevant exemption.

For further insights into IMNM stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyImmunome price target lowered to $21 from $23 at Piper Sandler
TipRanks Auto-Generated NewsdeskImmunome, Inc. Reports Q3 2024 Financial Results
TheFlyImmunome reports Q3 EPS (78c), consensus (56c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App